Evidence map›Paper›PMID 30324300›Full record

ArticleWiener klinische Wochenschrift2018

Abiraterone acetate, enzalutamide and their sequence for castration-resistant prostate cancer : Adherence, survival and hospitalization analysis of a medical claims database.

Badereddin Mohamad Al-Ali, Klaus Eredics, Stephan Madersbacher, Ingrid Schauer

Abstract read
PubMed Publisher
In one paragraph

Article in Wiener klinische Wochenschrift, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.1field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Badereddin Mohamad Al-AliDepartment of Urology, Kaiser-Franz-Josef Hospital, Kundratstraße 3, 1100, Vienna, Austria.
Klaus EredicsDepartment of Urology, Kaiser-Franz-Josef Hospital, Kundratstraße 3, 1100, Vienna, Austria.
Stephan MadersbacherDepartment of Urology, Kaiser-Franz-Josef Hospital, Kundratstraße 3, 1100, Vienna, Austria.
Ingrid SchauerDepartment of Urology, Kaiser-Franz-Josef Hospital, Kundratstraße 3, 1100, Vienna, Austria. ingrid_schauer@gmx.at.ORCID http://orcid.org/0000-0003-4094-3532
Kaiser-Franz-Josef-Spital · ATSigmund Freud Privatuniversität Wien · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo analyze drug adherence, overall survival (OS) and hospitalization rates of patients with castration-resistant prostate cancer (CRPC) treated with arbiraterone acetate (AA), enzalutamide (ENZ) and their sequence in a real-life setting.

methodsThe database of the largest public insurance company in Austria was analyzed. All CRPC patients with at least one prescription of AA and/or ENZ between September 2013 and August 2016 in the pre-chemotherapy and post-chemotherapy setting were extracted and matched to the Austrian death and hospital admission statistics. Drug adherence was estimated by the medication possession ratio (MPR).

resultsData of 457 patients (mean age: 74.4 ± 8.5 years) were analyzed. The mean MPR was 90% for AA, 85% for ENZ and 88% for the sequence therapy cohort. The median overall survival (OS) of the entire cohort was 21 months: 15 months for AA, 24 months for ENZ, 26 months for the sequence group, and 10 months for the sequence group after switching. In the post-chemotherapy setting, the median OS was 14 months in AA treatment (mean: 15.8 ± 0.9 months), 19 months in the ENZ treatment (mean: 17.2 ± 1.4 months) and 25 months in the sequence group (mean: 22.7 ± 0.8 months). Median OS in the pre-chemotherapy setting was 25 months (mean: 21.5 ± 1.1 months), 18 months in AA treatment group (mean: 18.9 ± 1.5 months) and 17 months in ENZ treatment group (mean: 18.2 ± 1.9 months). Only 43 (9.4%) patients were not hospitalized during the course of the study. On average patients spent 13% of their remaining life span in hospital care (median 8%, range: 1-34%).

conclusionThis Austrian prescription database allows some insights into the outcome of CRPC patients treated with AA and ENZ and their sequence in a real-life setting. Drug adherence was satisfactory, OS was shorter for AA and ENZ as compared to the pivotal phase III trials.

Indexed as

Prostatic Neoplasms, Castration-ResistantAbiraterone AcetateAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsAustriaBenzamidesHospitalizationHumansMaleNitrilesPhenylthiohydantoinTreatment OutcomeAbiraterone AcetateBenzamidesenzalutamideNitrilesPhenylthiohydantoinAbiraterone acetat (AA)Castration-resistant prostate cancer (CRPC)Enzalutamide (ENZ)Medication adherenceOverall survival (OS)

Identifiers

PMID30324300
OpenAlexW2897383654

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.